166809-18-3

Basic information

• Product Name: 3-[4-methoxycarbonyl-4-phenyl piperidin-1-yl]propylamine
• Synonyms: 3-[4-methoxycarbonyl-4-phenyl piperidin-1-yl]propylamine
• CAS NO: 166809-18-3
• Molecular Weight: 276.379
• Mol File: 166809-18-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 3-[4-methoxycarbonyl-4-phenyl piperidin-1-yl]propylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[4-methoxycarbonyl-4-phenyl piperidin-1-yl]propylamine(166809-18-3)
• EPA Substance Registry System: 3-[4-methoxycarbonyl-4-phenyl piperidin-1-yl]propylamine(166809-18-3)

Safety Data

• Hazardous Substances Data: 166809-18-3(Hazardous Substances Data)

Upstream product

• 54824-07-6 methyl 4-phenylpiperidine-4-carboxylate 
• 5003-71-4 3-bromopropylamine hydrochloride 
• 167262-47-7 1-tert-butyloxycarbonyl-4-phenyl-piperidine-4-carboxylic acid methyl ester 
• 101-41-7 benzeneacetic acid methyl ester 

Downstream Products

• 263023-74-1 5-(3,4-Difluorophenyl)-2,3-dihydro-4-methoxycarbonyl-1-(3-(4-methoxycarbonyl-4-phenylpiperidin-1-yl)prop-1-yl)aminocarbonyl-2(1H)-imidazolone 
• 179482-61-2 (+)-6-(3,4-Difluorophenyl)-1,6-dihydro-2-oxo-5-methoxy-carbonyl-4-bromomethyl-1-[(4-nitrophenyl-oxy)carbonyl]pyrimidine 
• 166808-37-3 5-[3-(4-methoxycarbonyl-4-phenyl-piperidin-1-yl)-propylcarbamoyl]-2,6-dimethyl-4-(4-nitro-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid 
• 179481-02-8 5-(cyanoethoxycarbonyl)-1,6-dihydro-4-ethyl-2-methoxy-1-{N-[3-(4-methoxycarbonyl-4-phenylpiperidin-1-yl)propyl]carboxamido}-6-(4-nitrophenyl)pyrimidine 
• 1027314-33-5 6-(3,4-difluoro-phenyl)-2-methoxy-1-[3-(4-methoxycarbonyl-4-phenyl-piperidin-1-yl)-propylcarbamoyl]-4-methyl-1,6-dihydro-pyrimidine-5-carboxylic acid methyl ester 
• 1026635-74-4 6-(2,4-difluoro-phenyl)-2-methoxy-1-[3-(4-methoxycarbonyl-4-phenyl-piperidin-1-yl)-propylcarbamoyl]-4-methyl-1,6-dihydro-pyrimidine-5-carboxylic acid methyl ester 
• 251930-30-0 2-methoxy-1-[3-(4-methoxycarbonyl-4-phenyl-piperidin-1-yl)-propylcarbamoyl]-4-methyl-6-(4-nitro-phenyl)-1,6-dihydro-pyrimidine-5-carboxylic acid methyl ester 

Relevant articles and documents

MORPHOLINONE AND MORPHOLINE DERIVATIVES AND USES THEREOF

This invention is directed to morpholinone and morpholine derivatives which are selective antagonists for human α 1a receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, sympathetic mediated pain, migraine, and for the treatment of any disease where the antagonism of the α 1a receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Oxazolidinones as alpha 1A receptor antagonists

This invention is directed to oxazolidinone compounds which are selective antagonists for human alpha 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the alpha 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

5-(HETEROCYCLIC ALKYL)-6-ARYL-DIHYDROPYRIMIDINES

This invention is directed to dihydropyrimidine compounds which are selective antagonists for human α 1C receptors and which have the structure: STR1 wherein A is aryl; R 1, R 2 and R. sub.3 are alkyl or heteroalkyl; R 4 is heterocyclic alkyl; and X is S, O or NR 3. This invention also relates to use of these compounds for the treatment of benign prostatic hyperplasia and other diseases where antagonism of the human α 1C receptor is useful. The invention further provides pharmaceutical compositions comprising a therapeutically effective amount of such a compound and a pharmaceutically acceptable carrier.